Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves’ disease
Maraviroc shows promise as a targeted therapy for TED in the context of GD, offering anti-inflammatory and anti-adipogenic benefits while sparing thyroid autoimmunity. These preclinical findings support further clinical investigation into its role in managing TED.
Authors
- Fahimeh Hashemi Arani
- Erich Gulbins (ORCID: https://orcid.org/0000-0002-3117-1342)
- Mareike Horstmann
- Anne Gulbins
- Gina-Eva Görtz (ORCID: https://orcid.org/0000-0003-3380-2635)
- Anke Daser
- Bechrakis N.E
- Anja Eckstein
- Insa Nolte
- J Paul Banga
Institutions
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fendo.2026.1717212
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen